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Background: Hypothermia is a rare, but potentially fatal adverse effect of antipsychotic 
drug (APD) use. Although the opposite condition, hyperthermia, has been researched 
extensively in the context of the malignant antipsychotic syndrome, little is known 
about hypothermia due to APDs.
Objective: This study aimed to review the literature on hypothermia in the context of 
APD use, and formulate implications for research and clinical care.
methods: A systematic search was made in PubMed and Ovid Medline.
Results: The literature search yielded 433 articles, including 57 original case descrip-
tions of hypothermia developed during APD use with non-toxic plasma levels. All 
cases together indicate that the risk of developing hypothermia is highest during the 
7 days following initiation, or increase in dosage, of APDs, especially in the presence 
of additional predisposing factors, such as advanced age, exposure to cold, adjuvant 
use of benzodiazepines, and (subclinical) hypothyroidism. In addition, data derived from 
drug-monitoring agencies suggest that the prevalence of APD-related hypothermia is at 
least 10 times higher than suggested by the literature.
conclusion: We conclude that health-care professionals need to monitor the body 
temperature of patients starting with (an increased dose of) APDs for a duration of 
7–10 days to prevent hypothermia, especially in the presence of multiple risk factors. 
Moreover, systematic studies are needed to establish the actual prevalence of APD-
related hypothermia as well as the relative risk for individual APDs.
Keywords: body temperature, neuroleptic, old age, side effect, thermoregulation
iNtRODUctiON
In humans, hypothermia is defined as a core body temperature (or rectal temperature, in clinical 
practice) of <35.0°C. Traditionally, three degrees of hypothermia are being distinguished, called 
mild hypothermia (33–35°C), moderate hypothermia (28–33°C), and severe hypothermia (<28°C) 
(1). After an initial phase of activation, hypothermia causes a process of progressive depression 
of all organ systems. Thus, mild hypothermia is characterized by heavy shivering, cold diuresis, 
and a cold, white skin; moderate hypothermia by reduced shivering, hyporeflexia, ataxia, and 
bradycardia; and severe hypothermia by the cessation of shivering, bradycardia (with possible 
cardiac arrest), hypotension, hypoventilation (with possible apnea), areflexia, oliguria, coma, and 
eventually death (2).
As various predisposing factors and underlying mechanisms are known for hypother-
mia, the condition is conceptualized as having a multifactorial etiology. The term “primary 
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hypothermia” is used when a low body temperature is attrib-
utable to environmental factors, including exposure to cold, 
poor heating, inadequate clothing, and poor nutrition (3). 
The term “secondary hypothermia” is used when it is attribut-
able to a medical condition, as exemplified by disorders of 
hypothalamic thermoregulation (4). However, hypothermia 
has also been reported in the context of the use of antipsy-
chotic drugs (APDs, neuroleptics), including clozapine (5), 
pipamperone (6), risperidone (7), olanzapine (8), aripiprazole 
(9), ziprasidone (10), and zotepine (11).
As the causative factors underlying APD-related hypo-
ther mia are in need of further elucidation, it remains unclear 
whether this condition deserves to be classified as a primary 
or secondary type of hypothermia, or perhaps as a tertiary 
(i.e., iatrogenic) type. Nevertheless, it is considered a rare, 
although potentially lethal, adverse effect of APD use, especially 
in the presence of other predisposing factors for hypothermia, 
such as advanced age, a cerebrovascular accident, (subclinical) 
hypothyroidism, sepsis, benzodiazepine use, alcohol intoxica-
tion, kidney or liver failure (4, 10), and possibly also poverty 
(12). To our knowledge, no systematic studies are available 
on the relative risk contributed by each of these factors, but 
APD use alone has been held accountable for at least some 
hypothermia-induced deaths (13).
The aim of this review is to critically assess the risk of hypo-
thermia in the context of regular APD use (i.e., outside the 
context of toxic plasma levels), to promote the awareness of this 
potentially lethal adverse effect among health-care professionals, 
to provide practical advice aimed at preventing and treating 
it, and to formulate objectives for future research.
mateRiaLS aND metHODS
For the present review, a systematic search was conducted 
in the PubMed and Ovid databases (up to May 2017). The 
Ovid database included EMBASE (1974 through May 2017), 
Ovid Medline (1946 through May 2017), and PsycINFO 
(1806 through May 2017). The search terms used were “hypo-
thermia,” “low body temperature,” and “thermoregulation,” 
which we combined with “antipsychotic” and “neuroleptic.” 
Included were all relevant papers written in English and Dutch. 
All cross-references were checked. Excluded were articles 
on hypothermia in animals and on hypothermia in humans 
coinciding with toxic plasma levels of APDs. Throughout 
this paper, we use the term “additional predisposing factor for 
hypothermia” when any factor, additional to the use of APDs, 
increases the risk of hypothermia even further. The Adverse 
Drug Reaction (ADR) Probability Scale, also known as the 
Naranjo Probability Scale (14), was used to assess the causal 
role of APDs in hypothermia.
ReSULtS
Literature Search
The literature search yielded 433 articles, of which 94 were 
considered relevant for the present review. These included 48 
case reports, with a total of 63 individual case descriptions. 
We excluded six cases because: (i) two of them were discussed 
twice in different publications [i.e., in Ref. (15–18)], (ii) three 
did not meet the criteria of hypothermia in the context of APD 
use (19–21), and (iii) one had an incomplete report (22). This 
resulted in 42 relevant case reports with a total number of 57 
original case descriptions (Table 1).
The mean age of these 57 patients was 55  years (range 
0–94), including a newborn who had been exposed in  utero. 
The median age was 54 years; 29 patients (51%) were male. The 
psychiatric diagnosis was known in 53 cases (93%), 26 of them 
(49%) being schizophrenia spectrum disorder and 6 (11%) 
bipolar disorder. In 33 patients (58%), hypothermia developed 
shortly after the initiation of antipsychotic treatment or a dose 
increase; in 9 of these patients (27%) this happened within 
2 days and in 14 (42%) after 2–7 days. Two patients (4%) died, 
with hypothermia being the most likely cause. For 50 patients 
(88%), one or more additional predisposing factors for hypo-
thermia (i.e., in addition to the use of APDs) were described in 
the original papers; in four cases (7%), there were no additional 
predisposing factors, and in the remaining three cases (5%), 
no mention was made of such factors. The mean number of 
additional predisposing factors per patient was 1.7 (range 0–4). 
The most prevalent ones were advanced age (25 cases, 46%), 
adjuvant use of benzodiazepines (20 cases, 37%), (subclinical) 
hypothyroidism (8 cases, 15%), and outdoor exposure to cold 
(8 cases, 15%) (Table 2).
With the aid of the Naranjo Probability Scale (14) we 
asses sed the contribution of each APD to the development of 
hypothermia. As some patients used multiple types of APD, we 
recorded 71 instances of APD use for the total number of 57 
cases. Table  3 provides an overview of the demographic and 
clinical characteristics of these 57 cases. The mean outcome of 
the Naranjo Probability Scale was 1.5 (0–7), with a median of 1, 
which is indicative of a possible ADR. Hypothermia developed 
most often in the context of the use of olanzapine (13 cases, 18%), 
haloperidol (13 cases, 18%), and risperidone (10 cases, 14%). 
However, as indicated by Table 4, hypothermia also developed 
in association with 14 other types of APD.
In all, 14 patients experienced more than one hypothermic 
episode (Tables  1 and 2). In these cases, the prescribed APD 
was nevertheless continued or reintroduced, after which some 
patients experienced yet another episode. Three patients expe-
rienced a second hypothermic episode after they had switched 
to a different APD. Nevertheless, Chen et al. (11), Kamp et al. 
(34, 35), and Goodbar et al. (27) describe four cases in which 
hypothermia did not recur after lowering of the dose, while 
Özyurt et al. (43) describe a case in which hypothermia did not 
recur after increasing the dose after an interval of 2 days.
DiScUSSiON
Historical Perspective
The potential effects of APDs on body temperature have been 
known since the discovery of chlorpromazine by Charpentier 
in 1950. During the early 1950s, when the compound was yet 
taBLe 1 | Cases of antipsychotic-related hypothermia.
case no. Reference minimum body  
temperature (°c)
antipsychotic Number of additional predisposing 
factors (characterization)
1 Al Chekakie et al. (15); Ginsberg (16) 33.4 Risperidone 1 (PAH)
2 Blass and Chuen (23) 33.4 Olanzapine 2 (PAH, MD)
3 Brandon Bookstaver and Miller (7) 32.5 Risperidone 3 (PAH, CNS, M)
4 Brevik and Farver (4) 33.3 Risperidone 1 (M)
5 Bueno de Mesquita and Balk (8) 27.0 Olanzapine 3 (PAH)
6 Chen et al. (11) <35.0 Zotepine 1 (M)
7 Chen et al. (11) 34.8 Zotepine 1 (M)
8 Chen et al. (24) 34.0 Zotepine 0
9 Chu and Nyfort-Hansen (25) 31.9 Olanzapine 4 (PAH, MD, O)
10 Eikenboom et al. (6) 31.8 Pipamperone 2 (PAH, MD)
11 Eikenboom et al. (6) 33.7 Pipamperone 3 (PAH, M, O)
12 Fukunishi et al. (26) <34.0 Olanzapine 1 (O)
13 Gibbons et al. (10) 29.4 Ziprasidone 1 (PAH)
14 Goodbar et al. (27) 32.8 Thioridazine 4 (CNS, MD, M)




16 Hamuro et al. (29) 32.9 Levomepromazine 1 (PAH)
Haloperidol
17 Hamuro et al. (29) 33.0 Levomepromazine 2 (PAH)
Zotepine
18 Hamuro et al. (29) 33.0 Sultopride 2 (PAH)
Haloperidol
19 Hamuro et al. (29) 34.3 Haloperidol 1 (PAH)
20 Harada et al. (30) 32.0 Haloperidol 3 (PAH, MD, M)
Chlorpromazine
21 Hung et al. (31) 34.9 Olanzapine 1 (M)
22 Jepsen and Jestrab (32) 29.9 Risperidone 1 (CNS)
23 Jordan et al. (33) 30.2 Risperidone 1 (PAH)
24 Kamp et al. (34, 35) 31.9 Risperidone 2 (PAH, M)
Pipamperone
25 Kamp et al. (34, 35) 34.1 Pipamperone 2 (PAH, M)
26 Kansagra et al. (36) 31.2 Olanzapine 2 (PAH, O)
27 Kreuzer et al. (17) 30.0 Olanzapine 3 (MD, M, O)
28 Kreuzer et al. (17, 18) 31.0 Olanzapine 2 (CNS, M)
29 Kreuzer et al. (17) 33.0 Olanzapine 1 (PAH)
30 Kreuzer et al. (17) Unknown Benperidol 1 (CNS)
31 Kreuzer et al. (17) 34.3 Benperidol 1 (M)
Levomepromazine
32 Lanska and Harsch (37) 33.3 Thioridazine 4 (PAH, CNS, MD, M)
33 Loughnane (38) 34.7 Chlorpromazine 2 (CNS)
34 MacDonell and Wrenn (39) 32.2 Haloperidol 2 (M, O)
35 MacDonell and Wrenn (39) 33.3 Haloperidol 3 (PAH, CNS, MD)
36 Martinez et al. (40) 29.9 Paliperidone 1 (CNS)
37 Mohan et al. (41) 35.0 Haloperidol 0
38 Noto et al. (42) <35.0 Zotepine 0
Fluphenazine
39 Özyurt et al. (43) 33.3 Clozapine 1 (M)
Aripiprazole
40 Papazizis et al. (5) 31.0 Clozapine 1 (PAH)
41 Parris et al. (44) 33.1 Olanzapine 2 (PAH, M)
42 Parris et al. (44) 32.0 Quetiapine 2 (PAH, M)
43 Pelechas et al. (45) 27.2 Haloperidol 3 (PAH, M)
44 Pelechas et al. (45) 27.6 Haloperidol 3 (PAH, CNS, M)
Clozapine
45 Perera and Yogaratnam (46) 33.3 Risperidone 1 (PAH)
46 Phan et al. (47) 27.0 Risperidone 3 (CNS, MD)
Olanzapine
47 Rasnayake et al. (48) 32.0 Olanzapine 0
48 Razaq and Samma (49) 32.8 Risperidone 2 (PAH)
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taBLe 4 | Antipsychotics and number of associations with hypothermia.
type of antipsychotic Number of associations of hypothermia as found 



















Due to the fact that various patients used more than one antipsychotic drug (APD), 
the number of associations between antipsychotics and hypothermia is larger than 
the number of patients. Moreover, as the number of people receiving individual APDs 
was unknown, the numbers in this table should not be taken as prevalence figures or 
relative risks.
taBLe 3 | Demographic and clinical characteristics of cases of hypothermia 
following antipsychotic drug use.
characteristics Data from the literature
Number of cases 57
Number of episodes 77
Males 29 (51%)
Age in years: mean (range), median 55 (0–94), 54
Unknown: 2 (4%)
Number of psychiatric diagnoses 53 (93%)
Schizophrenia/schizoaffective disorder 26 (49%)
Bipolar disorder 6 (11%)
Dementia 6 (11%)
Psychosis NOS 3 (6%)
Delirium 3 (6%)
Mental retardation 4 (8%)
Other 5 (9%)
Pharmacological intervention
Number of cases of hypothermia after  
start or dose increase of antipsychotic
33 (58%)






Number of deaths 2 (4%)
taBLe 2 | Predisposing factors for hypothermia, with examples per category [after Brevik and Farver (4)].
Primary accidental 
hypothermia
central nervous system metabolic disorders infections medication Other
Outdoor exposure to cold Seizures Hypoglycemia Sepsis Alcohol Renal failure
Sports-related Brain injury Thiamine deficiency Phenothiazines Hepatic failure
Inadequate or wet clothing Brain tumors Hypothyroidism Barbiturates Cardiac failure
Advanced age Cerebrovascular accident Hypopituitarism Benzodiazepines Starvation or malnutrition
Infants Hypothalamic disorders Adrenal insufficiency Cannabis Surgery, prolonged
Parkinson’s disease Narcotics Cardiopulmonary resuscitation
Spinal cord injury Tricyclic antidepressants Shock
Vasodilators: prazosin, terazosin Burns 
Regional or general anesthetics Exfoliative dermatologic disorders
Neuromuscular blockers Immobility or debilitation
case no. Reference minimum body  
temperature (°c)
antipsychotic Number of additional predisposing 
factors (characterization)
50 Sethi and Kavarum (51) 30.6 Ziprasidone 0
51 Sharma and Tikare (52) Unknown Chlorpromazine 1 (CNS)
52 Signorelli et al. (53) 33.2 Haloperidol Unknown
53 Signorelli et al. (53) 34.2 Haloperidol Unknown
54 Signorelli et al. (53) 33.6 Haloperidol Unknown
55 Van Marum et al. (54) 32.0 Levomepromazine 1 (CNS)
56 Van Marum et al. (54) 29.7 Risperidone 1 (CNS)
57 Young (13) 34.4 Molidone 3 (PAH, CNS)
Mean: 1.7 (0–4)
PAH, primary accidental hypothermia; CNS, central nervous system; MD, metabolic disorder; I, infection; M, medication; O, other.
taBLe 1 | Continued
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to be marketed as an “antipsychotic,” it was used during surgery 
to suppress the body’s response to cooling (55, 56). In a similar 
vein, Ferguson et al. (57) describe the case of a 69-year-old female 
who suffered from spontaneous, recurrent hypothermia for years 
on end, probably due to an agenesis of the corpus callosum, 
who was treated successfully with the aid of 25–50 mg of chlor-
promazine. As an aside, it is noteworthy that during the 1950s 
hypothermia was investigated as a potential treatment method 
for schizophrenia (58). Interestingly, Chong and Castle (59) 
later found that individuals diagnosed with schizophrenia have 
5
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different baseline temperatures to begin with, although in their 
study the role of APD use was identified as a possible confounder. 
Heh et al. (60) found that haloperidol and clozapine both have 
the potential to lower the body temperature compared to baseline 
(measured orally in their study), while Shiloh et al. (61) found 
that the initiation of APD use in male, medication-naive patients 
diagnosed with schizophrenia is associated with a persistent 
decrease in body temperature, albeit within the normal range. 
Likewise, Kudoh et al. (62) found that patients diagnosed with 
schizophrenia who use APDs have a lower body temperature 
during surgery than controls.
Antipsychotic drug-related hypothermia was first described 
by Loughnane (38) in a patient treated with chlorpromazine, 
and APD-related hyperthermia 8 years before that by Delay et al. 
(63). Today hyperthermia is the better known adverse effect, as 
it features prominently in the malignant antipsychotic syndrome 
(MAS, formerly known as malignant neuroleptic syndrome). 
This other potentially lethal failure of thermoregulation due 
to APDs has been researched extensively (64). For unknown 
reasons, hypothermia has received less attention (29, 65), even 
though a search by van Marum et al. (54) in the World Health 
Organization’s Adverse Drug Reaction Database indicated that an 
almost equal number of reports had been filed on hypothermia 
as on hyperthermia in relation to APD use (480 versus 524 cases, 
respectively). An important reason for this inequality may be 
that—notably mild—hypothermia tends to present with rather 
subtle and atypical symptoms, such as confusion, vertigo, nau-
sea, hunger, chills, pruritus, and dyspnea (4) and may, therefore, 
easily go unnoticed. Moreover, as measurement of the body 
temperature of patients using APDs is not standard practice 
and health professionals and researchers may not be familiar 
with all predisposing factors (Table  2), in clinical practice, 
many cases may have been missed and, therefore, the problem 
underestimated.
Physiology
Maintaining a stable core temperature is a major homeostatic 
function critical to survival. Under normal circumstances, 
the human body functions optimally at a core temperature of 
36.4–37.5°C (66). To our knowledge, the prevalence of hypo-
thermia in the general population has never been studied 
systematically. The normal range for men (measured rectally) is 
36.7–37.5°C, and for women 36.8–37.1°C. Measured tympani-
cally, it is 35.5–37.5°C for men and 35.7–37.5°C for women (67). 
Normal thermoregulation involves maintaining a dynamic bal-
ance bet ween heat production, heat conservation, and heat loss 
(68). This complex and intruiging process is not fully understood, 
but involves at least thermal sensation, hypothalamic integra-
tion, and various central feedback mechanisms (69). The general 
idea is that thermoregulation is centrally coordinated by the 
hypothalamus, on the basis of feedback from the skin’s cold and 
heat receptors (1). Heat conservation is promoted by peripheral 
vasoconstriction and behavioral responses. Heat production is 
promoted by shivering as well as non-shivering thermogenesis, 
the latter via increases in levels of thyroxine and epinephrine 
(70). The hypothalamus has the role of integrating the autonomic, 
endocrine, and motor systems involved, including the body’s 
behavioral responses (69). Although the body’s core temperature 
may fluctuate slightly in a diurnal fashion, it is normally main-
tained within a relatively narrow range of 0.2–0.5°C, mainly by 
virtue of adjustments of skin vasomotor responses. Only larger 
downward fluctuations tend to result in a shivering response 
(1, 71). The most important brain regions for thermoregulation, 
as currently known, are the medial preoptic/anterior hypotha-
lamic area (POA), the dorsomedial nucleus of the hypothalamus, 
the periadequeductal gray matter of the midbrain, and the 
nucleus raphe pallidus in the medulla, of which the POA is the 
most thermosensitive area. The neurotransmitters dopamine, 
norepinephrine, and serotonin play important roles in this pro-
cess, together with the corresponding receptors upon which they 
act, i.e., the D1, D2, alpha-1, 5-HT-1, and 5-HT-2 receptors (69).
Pathophysiology
In the literature on human body temperature regulation, hypo-
thermia is attributed either to heat loss, abnormalities of heat 
conservation or production, failures of central thermoregu-
lation, or a combination thereof (72). Brevik and Farver (4) 
distinguish six main etiological groups of hypothermia, com-
prising (1) primary accidental hypothermia, (2) central nerv-
ous system disorders, (3) metabolic disorders, (4) infections, 
(5) medications, and (6) other (i.e., not otherwise specified) 
disorders (Table  2). These etiological groups are thought to 
have different (albeit partly overlapping) pathophysiological 
mechanisms. The mechanism underlying outdoor exposure 
to cold is peripheral heat loss, in (subclinical) hypothyroidism 
it is the impaired conversion of substrate to thermal energy 
(and thus the inability to produce sufficient heat), whereas 
in advanced age and sedation due to benzodiazepine use, the 
mechanism is the reduction of physical activity and the ability 
to shiver which, in turn, limits the ability to produce sufficient 
heat (72, 73). In the context of APD use the exact mechanism 
is unclear, although it is hypothesized that the inappropriate 
conservation of heat may (in such cases) be due to peripheral 
vasodilatation as well as a failure of central thermoregulation 
(8, 39, 65, 74). It is further hypothesized that the inhibition of 
peripheral responses to cooling may be due to an antagonism of 
alpha-adrenergic receptors. This might explain hypothermia in 
the context of the use of chlorpromazine, risperidone, clozap-
ine, and thioridazine, which all act as alpha-adrenergic receptor 
antagonists (54). In mice studies, Boshi et  al. (75) found that 
peripheral alpha-adrenoceptors may also be involved in the 
mediation of APD-induced hypothermia.
Under physiological circumstances, D2-receptors help to keep 
the body’s core temperature at a constant level, while D1-receptors 
are believed to play a modulating role. This explains why massive 
antagonism of the D2-receptor may entail a dramatic increase 
in body temperature, as is the case in MAS. Similarly, decreases 
in the body’s core temperature are linked to antagonism of the 
D1-receptor. As stimulation of the 5-HT-1-receptor results in a 
decrease of body temperature and stimulation of the 5-HT-2-
receptor in an increase, it is hypothesized that antagonism of the 
5-HT-2-receptor may be the cause of hypothermia in patients 
who use pipamperone or second-generation APDs, which act 
on this receptor (8, 18, 54, 74). De Langen-Wouterse and van 
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Grootheest (9), who studied the adverse effects of aripiprazole, 
proposed that hypothermia coinciding with the latter APD may 
be mediated by a partial agonistic effect on the 5-HT-1A-receptor.
Sudden Death
In the literature examined for this review, there were two descrip-
tions of deaths associated with APD-related hypothermia. One 
involved a 45-year-old male, diagnosed with schizophrenia, 
who developed hypothermia after the start of benperidol and 
who died due to circulatory failure and coagulation disorder 
with infarctions of the central nervous system (17). The second 
one involved a 67-year-old male, also diagnosed with schizo-
phrenia, who developed moderate hypothermia during risp-
eridone use and died due to cardiac arrest (33). Both deaths 
occurred within days after the patients had been found to be 
hypothermic. In a retrospective study of drug and alcohol use 
in hypothermia- and hyperthermia-related deaths, APDs had 
been used by 5 out of 46 patients (11%) who had died while 
being hypothermic. In two of these cases (4%) alcohol had also 
played a role (76). It is suggested that, in addition to these two 
cases, a substantial number of unexpected and sudden deaths 
among psychiatric patients over the past 60 years may also be 
attributable to APD-induced hypothermia (13). The underlying 
mechanism may have been ventricular fibrillation and asystole 
during the final stages of severe hypothermia. In such cases, 
in the absence of any signs of frostbite, hypothermia might 
easily have been overlooked as a possible cause of death (13). 
In a survey of 49 cases of sudden deaths associated with the use 
of APDs and/or antidepressants, Methonen et al. (77) failed to 
establish such a causal relation. This may illustrate how difficult 
it is to come to grips with the subject matter in the absence of a 
systematic study design. Nonetheless, the authors warn against 
the potential arrhythmogenic effects of APDs.
Another factor to increase the risk of death in APD-related 
hypothermia is the tendency of cold victims to withdraw and 
undress themselves, known in the literature as paradoxical 
undressing and the hide-and-die syndrome (78). The hide-and-
die syndrome coincides with 20% of cases of lethal hypother-
mia, based on the observation of forensic experts that the 
bodies of people who die of hypothermia are sometimes found 
in hidden places (e.g., under a bed or behind a wardrobe). This 
striking behavior in the face of imminent death is attributed to 
a primitive reaction pattern, possibly triggered and controlled 
by the brain stem (78). The term “paradoxical undressing” is 
used when people who experience hypothermia are found 
partly or completely undressed. The mechanism underlying 
this behavior is not fully understood, but may be related to 
a thermal illusion during severe hypothermia, brought about 
either by reflex vasoconstriction and an ensuing paralysis of 
the vasomotor center, or cold-induced paralysis of the nerves 
in the vessel walls which, in turn, leads to vasodilatation and a 
paradoxical sensation of heat (78).
clinical Practice
In clinical practice, the management of APD-related hypother-
mia starts with prevention. Therefore, Eikenboom et al. (6) advise 
to think twice before prescribing APDs, especially in elderly 
patients. Chahine et al. (79) agree with this, and moreover, advise 
to stay with atypical APDs because of the alleged lower risk of 
hypothermia. This is at odds, however, with the finding by van 
Marum et al. (54) in that 55% of the cases of hypothermia occur 
in the context of atypical APD use (which was found to be 52% in 
our own analysis). Considering the role of the D1- and 5-HT-2-
receptor in thermoregulation, this should perhaps not come as 
a surprise. All in all, warnings such as those above should not 
distract us from the fact that, as far as we know, hypothermia 
may affect anyone using any type of APD, including atypical ones, 
under widely varying circumstances. This is further indicated by 
reports such as those by Hung et al. (31), who described hypo-
thermia in an adolescent, by Mohan et al. (41), who described it 
in a newborn whose mother was treated with haloperidol during 
pregnancy, and by MacDonell and Wrenn (39), who described 
two cases that occurred during summer, in a warm environment, 
in the presence of two, respectively three, additional predispos-
ing factors. Although there is currently insufficient evidence 
to justify standard screening of the body temperature in all 
patients receiving a prescription for an APD, individuals at risk 
deserve to be identified and subsequently monitored.
Van Marum et al. (54) found that 80% of the cases of APD-
related hypothermia set in shortly after the start of medication or 
a dose increase, and, in 73% of these cases, within the first 7 days. 
This is roughly comparable to the results of our own analysis, 
which indicates that 58% of the cases set in after initiation or 
dose increase, 69% of which occurred during the first 7  days. 
In sum, the first week after APD prescription or dose increase 
would seem to be the most vulnerable episode. To prevent 
APD-related hypothermia without unnecessarily burdening 
both patient and staff, it seems safe to limit temperature meas-
urements to a period of 7–10 days after any initiation or dose 
increase of APDs. This can be done in several ways and with the 
use of several devices.
In biomedicine, oral, axillary, and rectal measurements are 
made with the aid of mercury-in-glass thermometers (although 
they are now banned in most European countries), tympanic 
measurements with infrared thermometers, and intra-arterial 
measurements with needle thermocouples. For most clinical 
purposes, rectal and tympanic measurements are considered 
sufficiently reliable, although for accurate results it is manda-
tory to use a thermometer specifically tested and validated for 
temperatures below 35°C (2). Meanwhile, the presence of any 
additional predisposing factors should be assessed. In proven 
cases of hypothermia, an electrocardiogram is advisable to detect 
the presence of bradycardia and/or Osborn waves, which are 
characteristic (although not pathognomonic) of hypothermia 
(80). Blood tests are then necessary to screen for acidosis, throm-
bocytopenia, and other coagulopathies, and to assess kidney as 
well as liver function (2).
treatment
The symptomatic treatment of hypothermia involves gradual 
rewarming, during and after which the patient’s vital signs are 
strictly monitored (2). Mild hypothermia is best treated by 
passive external rewarming, e.g., with blankets or other types 
of isolation material. Moderate hypothermia, as well as mild 
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hypothermia resistant to passive rewarming, is best treated with 
active external rewarming, e.g., with warm blankets. Severe 
hypothermia requires treatment on an ICU where warm intra-
venous fluids can be administered and continuous monitoring of 
vital functions is possible. Comorbid hypotension is best treated 
with volume resuscitation and, in therapy-resistant cases, with 
low doses of inotropic drugs such as dopamine. In this context, 
bradycardia is usually unresponsive to atropine, but the heart 
rate tends to restore during rewarming, as do blood pressure and 
coagulation disorders, if present (2). Thus treated, most cases 
of APD-related hypothermia tend to resolve within 24–48  h, 
although Kansagra et al. (36) and Chen et al. (24) both described 
a patient who needed 9 days. In such cases, it might seem obvious 
to interrupt or cease the administration of APDs; however, the 
question whether this is necessary is not easily answered in the 
face of the current evidence. As we saw, hypothermia has been 
described in the context of at least 17 different types of APD, 
while in the case series of 57 patients described above, only 14 
patients experienced more than one hypothermic episode, three 
of which, moreover, after switching to a different type of APD 
(Tables  1 and 2). Therefore, only in the face of overwhelm-
ing evidence that additional risk factors did not play a major 
role in causing hypothermia, we do recommend to stop the 
APD currently used during rewarming. When additional risk 
factors are present, or stopping the APD is not possible, the 
original treatment can be continued under strict monitoring of 
the temperature and other vital functions. What may be con-
sidered then, instead, is lowering the dose. After normalization 
of the temperature, there seems to be no strict contraindication 
for reintroducing the same APD or readministering it at its 
initial dose. What warrants proper attention, however, is the 
(conti nuing) presence of additional risk factors for hypothermia.
cONcLUSiON
With 57 reports, the number of published cases on APD-related 
hypothermia is small, especially considering the widespread use 
of these types of medication worldwide. However, according 
to drug-monitoring databases, this potentially lethal complica-
tion of APD use is at least 10 times that suggested by published 
reports. Therefore, health professionals need to be aware of 
hypothermia as a possible adverse effect of APDs, especially in 
patients with additional predisposing factors for hypothermia 
who are starting with an APD or whose dose is being increased. 
Strict monitoring of the body temperature for a duration of 
7–10  days is a simple and effective way to prevent complica-
tions. Meanwhile, systematic research is needed to shed more 
light on the issue of thermoregulation in patients diagnosed with 
schizophrenia, and on the relative risk of all types of APD for 
mediating hypothermia, whether or not in the presence of any 
other predisposing factors.
Limitations
The literature on APD-related hypothermia is limited, especially 
compared with that on APD-related hyperthermia. Due to the 
lack of systematic studies, the actual prevalence of this adverse 
effect is as yet unknown, as is the relative risk for hypothermia 
for each individual APD and chemical class of APDs in the 
context of the number of people receiving them. Nevertheless, 
based on the literature and the above analysis, hypothermia is 
considered a tangible, and potentially lethal adverse effect of 
APDs; that said, however, the finding that this is especially true 
in the presence of other predisposing factors for hypothermia, 
begs the question of whether these predisposing factors alone 
might not be sufficient cause for the body temperature to drop. 
After all, the prevalence of idiopathic hypothermia in the general 
population is as yet unknown. In other words, a skeptic’s point of 
view might be that the role of APDs in mediating hypothermia 
may as well be under- as overestimated. However, the suspicion 
that APD-related hypothermia is not a naturally occurring 
disorder, but rather a (potentially fatal) iatrogenic condition, 
warrants further study and ongoing efforts to prevent and treat 
it in clinical practice.
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